Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma
Cette étude analyse l'association entre l'efficacité des inhibiteurs de points de contrôle immunitaire anti-PD-1/PD-L1 et des altérations génomiques, chez des patients atteints d'un carcinome à cellules rénales de stade avancé, en fonction de l'indice de masse corporelle
An elevated body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) has been associated with an increased risk of renal cell carcinoma (RCC). Previously, higher BMI was shown to be a positive prognostic factor for patients with metastatic clear cell RCC (mRCC) who were treated during the vascular endothelial growth factor (VEGF)–targeted therapy era. However, the treatment landscape has shifted to include immune checkpoint inhibitors (ICIs) for most patients. We investigated this obesity paradox in patients with mRCC who were treated with programmed cell death 1 protein/programmed cell death 1 ligand 1 (PD-1/PD-L1)–based ICIs and explored potential genomic alterations according to BMI status.